United States–headquartered animal health company Zoetis has invested A$350 million to expand its manufacturing site in Victoria. The investment supports the company’s future ability to develop and manufacture vaccines, medicines and diagnostic tools for livestock and domestic animals.
The investment will increase Zoetis footprint at the site by 5 times and create 95 jobs.
Zoetis manufactures around 130 million vaccines for livestock and domestic animals in Australia each year. The company sold A$484 million of products in Australia in 2023, an increase of 17% over the previous year. It employs 426 people in Australia across its commercial, manufacturing and R&D teams.
‘We are excited to increase our investment in Australia and provide greater support to Australia’s farmers and veterinarians,’ says Kristin Peck, CEO, Zoetis.
‘Australia’s livestock sector is highly regarded around the world. Zoetis is proud to help the region’s livestock farmers be part of a climate solution as they increase productivity, health and welfare outcomes that can have a positive impact on the planet.’
Zoetis’ site is in the Parkville Precinct, a leading hub in Victoria for biomedical innovation and advanced manufacturing. The company has been operating at the site since 2004, producing vaccines for cattle, sheep, horses, dogs, cats and pigs.
The Parkville site expansion follows Zoetis’ acquisition of animal health company Jurox in 2022. This provided the company with a second Australian manufacturing site in the Hunter Valley, in New South Wales.
Australia’s advanced manufacturing industry focuses on high-value sectors including energy, infrastructure, defence, aerospace, health and agrifood. We offer a strategic location for decentralised or distributed manufacturing with access to key export markets. There is strong government support for industry innovation and commercialisation, including tax incentives and grants.
Zoetis worked with Austrade to identify possible sites for its manufacturing facility. Austrade also:
Find out about new investment opportunities, insights and investor success stories across Australia.